The main pathological features of multiple sclerosis, demyelination and axonal transection, are considered to cause reversible and irreversible neurological deficits, respectively. This study aimed to separately analyze the effects of these pathological hallmarks on neuronal gene expression in experimental paradigms. The pontocerebellar pathway was targeted with either lysolecithin-induced chemical demyelination or a complete pathway transection (axonal transection) in rats. Transcriptional changes in the pontocerebellar neurons were investigated with microarrays at days 4, 10 and 37 post-intervention, which was confirmed by immunohistochemistry on protein level. A common as well as unique set of injury-response genes was identified. The increased expression of activating transcription factor 3 (Atf3) and thyrotropin-releasing hormone (Trh) in both injury paradigms was validated by immunohistochemistry. The expression of Atf3 in a patient with Marburg’s variant of multiple sclerosis was also detected, also confirming the activation of the Atf3 pathway in a human disease sample. It was concluded that this experimental approach may be useful for the identification of pathways that could be targeted for remyelinative or neuroprotective drug development.
Prineas JW, Connell F.The fine structure of chronically active multiple sclerosis plaques. Neurology1978; 28: 68-75.
2.
Storch M., Lassmann H.Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol1997; 10: 186-192.
3.
Lovas G., Palkovits M., Komoly S.A molecular element of neuronal response to lysolecithin-induced focal, experimental demyelination in rat. Neurobiology (Bp)2000; 8: 273-275.
4.
Trapp BD, Peterson J., Ransohoff RM, Rudick R., Mork S., Bo L.Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1-29-1998; 338: 278-285.
5.
Ferguson B., Matyszak MK, Esiri MM, Perry VHAxonal damage in acute multiple sclerosis lesions. Brain1997; 120(Pt 3): 393-399.
6.
Lovas G., Szilagyi N., Majtenyi K., Palkovits M., Komoly S.Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain2000; 123(Pt 2): 308-317.
7.
Arnold DL, Wolinsky JS, Matthews PM, Falini A.The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry1998; 64(Suppl 1): S94-101.
8.
De Stefano N. , Matthews PM, Fu L., Narayanan S., Stanley J., Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain1998; 121(Pt 8): 1469-1477.
9.
Falini A., Calabrese G., Filippi M., Origgi D., Lipari S., Colombo B., et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability . AJNR Am J Neuroradiol1998; 19: 223-229.
Simmons ML, Frondoza CG, Coyle JTImmunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies . Neuroscience1991; 45: 37-45.
12.
Lucchinetti C., Bruck W., Noseworthy J.Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment . Curr Opin Neurol2001; 14: 259-269.
13.
Palkovits M.Neuropeptide messenger plasticity in the CNS neurons following axotomy. Mol Neurobiol1995; 10: 91-103.
14.
Agoston DV, Komoly S., Palkovits M.Selective up-regulation of neuropeptide synthesis by blocking the neuronal activity: galanin expression in septohippocampal neurons. Exp Neurol1994; 126: 247-255.
Abankwa D., Kury P., Muller HWDynamic changes in gene expression profiles following axotomy of projection fibres in the Mammalian CNS. Mol Cell Neurosci2002; 21: 421-435.
17.
Del Signore A., De Sanctis V., Di Mauro E., Negri R., Perrone-Capano C., Paggi P.Gene expression pathways induced by axotomy and decentralization of rat superior cervical ganglion neurons. Eur J Neurosci2006; 23: 65-74.
18.
Dutcher SA, Michael DBGene expression in neurotrauma. Neurol Res2001; 23: 203-206.
19.
Shortland PJ , Baytug B., Krzyzanowska A., McMahon SB, Priestley JV, Averill S.ATF3 expression in L4 dorsal root ganglion neurons after L5 spinal nerve transaction. Eur J Neurosci2006; 23: 365-373.
20.
Yakovlev AG , Faden AIMolecular biology of CNS injury. J Neurotrauma1995; 12: 767-777.
21.
Greenberg SAMicroarray analysis of human nervous system gene expression in neurological disease. Int Rev Neurobiol2004; 60: 135-151.
22.
Arnett HA, Wang Y., Matsushima GK, Suzuki K., Ting JPFunctional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 10-29- 2003; 23: 9824-9832.
23.
Kotter MR, Setzu A., Sim FJ, Van Rooijen N., Franklin RJMacrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia2001; 35: 204-212.
24.
Lovas G., Palkovits M., Komoly S.Increased c-Jun expression in neurons affected by lysolecithin-induced demyelination in rats. Neurosci Lett 10-6-2000; 292: 71-74.
25.
Woodruff RH , Franklin RJDemyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: a comparative study . Glia 2-1-1999; 25: 216-228.
26.
Woodruff RH , Franklin RJGrowth factors and remyelination in the CNS . Histol Histopathol1997; 12: 459-466.
27.
Woodruff RH , Franklin RJThe expression of myelin protein mRNAs during remyelination of lysolecithin-induced demyelination. Neuropathol Appl Neurobiol1999; 25: 226-235.
28.
Fressinaud C., Jean I., Dubas F.[Lesion mechanism dependent, differential changes in neurofilaments and microtubules: a pathological and experimental study]. Rev Neurol (Paris) 2005; 161: 55-60.
29.
Gilson J., Blakemore WFFailure of remyelination in areas of demyelination produced in the spinal cord of old rats. Neuropathol Appl Neurobiol1993; 19: 173-181.
30.
Canellas AR , Gols AR, Izquierdo JR, Subirana MT, Gairin XMIdiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology2007; 49: 393-409.
31.
Halasz B., Florsheim WH, Corcorran NL, Gorski RAThyrotrophic hormone secretion in rats after partial or total interruption of neural afferents to the medial basal hypothalamus. Endocrinology1967; 80: 1075-1082.
32.
Saavedra JM , Palkovits M., Brownstein MJ, Axelrod J.Localisation of phenylethanolamine N-methyl transferase in the rat brain nuclei. Nature 4-19- 1974; 248: 695-696.
33.
Weaver DR, Deeds JD, Lee K., Segre GVLocalization of parathyroid hormone-related peptide (PTHrP) and PTH/ PTHrP receptor mRNAs in rat brain. Brain Res Mol Brain Res1995; 28: 296-310.
34.
Herdegen T. , Kovary K., Leah J., Bravo R. Specific temporal and spatial distribution of JUN, FOS, and KROX-24 proteins in spinal neurons following noxious transsynaptic stimulation. J Comp Neurol 11-1-1991; 313: 178-191.
35.
Mason MR, Lieberman AR, Anderson PNCorticospinal neurons up-regulate a range of growth-associated genes following intracortical, but not spinal, axotomy. Eur J Neurosci2003; 18: 789-802.
36.
McCampbell A., Truong D., Broom DC, Allchorne A., Gable K., Cutler RG, et al. Mutant SPTLC1 dominantly inhibits serine palmitoyltransferase activity in vivo and confers an age-dependent neuropathy. Hum Mol Genet 11-15-2005; 14: 3507-3521.
37.
Tsujino H., Kondo E., Fukuoka T., Dai Y., Tokunaga A., Miki K., et al. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury. Mol Cell Neurosci2000; 15: 170-182.
38.
Dickson TC, Adlard PA, Vickers JCSequence of cellular changes following localized axotomy to cortical neurons in glia-free culture. J Neurotrauma2000; 17: 1095-1103.
39.
Tanabe K., Bonilla I., Winkles JA, Strittmatter SMFibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci 10-22- 2003; 23: 9675-9686.
40.
Verhaagen J. , Zhang Y., Hamers FP, Gispen WHElevated expression of B-50 (GAP-43)-mRNA in a subpopulation of olfactory bulb mitral cells following axotomy. J Neurosci Res 6-1-1993; 35: 162-169.
41.
Zein EF, Karaa SE, Rollot F., Blanche P., Chemaly RETreatment of central pontine myelinolysis with thyrotropin-releasing hormone . Presse Med2006; 35: 618-620.
Fekete C., Sarkar S., Lechan RMRelative contribution of brainstem afferents to the cocaine- and amphetamine-regulated transcript (CART) innervation of thyrotropin-releasing hormone synthesizing neurons in the hypothalamic paraventricular nucleus (PVN). Brain Res 1-25-2005; 1032: 171-175.
44.
Kira J., Harada M., Yamaguchi Y., Shida N., Goto I.Hyperprolactinemia in multiple sclerosis. J Neurol Sci1991; 102: 61-66.
45.
Bonilla IE, Tanabe K., Strittmatter SMSmall prolinerich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci 2-15- 2002; 22: 1303-1315.
46.
Leaner VD, Kinoshita I., Birrer MJAP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets. Oncogene 8-28- 2003; 22: 5619-5629.
47.
Liu C., Shi Y., Du Y., Ning X., Liu N., Huang D., et al. Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Exp Cell Res 10-1-2005; 309: 410-418.
48.
Wek RC, Jiang HY, Anthony TGCoping with stress: eIF2 kinases and translational control. Biochem Soc Trans2006; 34: 7-11.
